DELFI Diagnostics has appointed Dr. Amoolya Singh as Chief Technology Officer to lead the company’s technology strategy and advance its AI-powered fragmentomics platform for early cancer detection. Dr. Singh joins a distinguished leadership team with expertise in cancer detection and treatment monitoring, supported by clinical trials and global research partnerships.
With over 20 years of experience in biotechnology and computational science, Dr. Singh previously served as Grail's Senior Vice President of Data Science and Chief Scientific Officer. She has also held leadership roles at Calico and Amyris. Dr. Singh’s expertise in developing and scaling complex diagnostic platforms will be instrumental as DELFI Diagnostics continues to innovate in blood-based cancer detection.
Dr. Singh holds a Ph.D. in Computational Biology from UC Berkeley and a B.S. in Biology and Computer Science from Carnegie Mellon University.
